Ovagen (EDL)
EDL Tripeptide · Liver & GI Bioregulator
Overview
Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.
Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.
Reduces long-term fibrosis development in liver tissue.
Protects liver through gene expression regulation.
Helps protect GI mucosal layer from various insults.
May protect GI tract from antibiotic-induced damage.
Mechanism
Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.
Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.
Reduces long-term fibrosis development in liver tissue.
Research areas
- Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.
- Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.
- Reduces long-term fibrosis development in liver tissue.
- Protects liver through gene expression regulation.
- Helps protect GI mucosal layer from various insults.
- May protect GI tract from antibiotic-induced damage.
- Protects against environmental toxin effects on GI tract.
- Addresses age-related liver changes through bioregulation.
- Supports GI tract function during aging.
Research notes
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual GI or liver symptoms
- Active liver emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
FAQs
How does Ovagen protect your gut from antibiotic damage?
Ovagen (EDL tripeptide) works by protecting the GI mucosal layer from antibiotic-induced damage. The peptide is transported via PEPT1/PEPT2 transporters directly to gut tissue where it regulates gene expression to strengthen mucosal integrity. Taking Ovagen during and after antibiotic courses may help preserve your microbiome.
Can I use Ovagen if I'm taking other Khavinson bioregulators?
Yes. Ovagen combines synergistically with Livagen, Epitalon, and other Khavinson peptides since they target different tissues. Many anti-aging protocols use multiple bioregulators together—Ovagen for liver/GI, Epitalon for telomeres, etc. Follow recommended cycling protocols to avoid overstimulation.
How long does it take Ovagen to reduce liver fibrosis?
Results are cumulative. During a 10-20 day cycle, gene expression changes begin immediately, but visible improvements in liver fibrosis occur over weeks to months with periodic cycles. The file recommends 2-3 cycles yearly for maintenance, suggesting ongoing use is needed for long-term fibrosis reduction.
Is Ovagen better taken as a capsule or injection?
Both routes work, but oral capsules are more convenient for daily dosing and room-temperature storage. Injectable forms offer direct absorption but require refrigeration and reconstitution. Choose based on your preference for convenience (capsules) vs. guaranteed absorption (injection).